Lakewood-Amedex is a clinical-stage biotechnology company that develops antimicrobial therapies to treat infections caused by antibiotic-resistant bacteria. The company's core technology is its proprietary Bisphosphocin class of synthetic nucleotide derivatives, which destroy bacterial cell membranes. Lakewood-Amedex's lead product candidate is Nu-3, a topical gel formulated to treat infected diabetic foot ulcers by delivering antimicrobial compounds directly to wound sites. The company is evaluating Nu-3 in clinical trials and plans to advance earlier-stage pipeline candidates, including Nu-8, Nu-10, and Nu-11, for catheter-associated urinary tract infections and pulmonary infections. As a pre-revenue drug developer, Lakewood-Amedex operates an R&D-driven business model and outsources all clinical manufacturing to contract development and manufacturing organizations. The company's strategy focuses on advancing Nu-3 through clinical trials to secure regulatory approval, expanding Nu-3 into additional wound and skin infection indications, progressing preclinical candidates, and seeking commercialization or development partnerships with established pharmaceutical companies.